Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 27 Dec 2021
Ligand’s Partner CStone Pharmaceuticals receives approval in China for sugemalimab (Cejemly) for the first-line treatment of advanced non-small-cell lung cancer in combination with chemotherapy
22 December 2021 - Sugemalimab was discovered using the OmniAb platform. ...
Posted by Michael Wonder on 26 Dec 2021
Public Summary Documents – September 2021 PBAC meeting
24 December 2021 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the September 2021 PBAC ...
Posted by Michael Wonder on 26 Dec 2021
PBS expenditure and prescriptions report 2020-21
24 December 2021 - The PBS Expenditure and Prescriptions Report 1 July 2020 to 30 June 2021 is now available. ...
Posted by Michael Wonder on 26 Dec 2021
Report on the collection of under co-payment data 2020-21
24 December 2021 - The report on the collection of under co-payment data 2020-21 is now available. ...
Posted by Michael Wonder on 26 Dec 2021
Lion TCR receives FDA fast track designation for its HBV specific TCR T cell therapy for hepatocellular carcinoma
23 December 2021 - Lion TCR today announced that it has received fast track designation from U.S. FDA for LioCyx-M004, autologous ...
Posted by Michael Wonder on 26 Dec 2021
Patritumab deruxtecan granted U.S. FDA breakthrough therapy designation in patients with metastatic EGFR mutated non-small-cell lung cancer
23 December 2021 - First breakthrough therapy designation for patritumab deruxtecan based on results of Phase 1 trial. ...
Posted by Michael Wonder on 26 Dec 2021
Children and young people set to benefit from new treatment for peanut allergy
23 December 2021 - Children and young people aged between 4 and 17 with a peanut allergy could be set to ...
Posted by Michael Wonder on 26 Dec 2021
Coherus announces U.S. FDA approval of Yusimry (adalimumab-aqvh)
20 December 2021 - Approved for all eligible indications of the reference biological product, Humira (adalimumab). ...
Posted by Michael Wonder on 26 Dec 2021
Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis related arthritis and psoriatic arthritis
22 December 2021 - New approvals are based on JUNIPERA trial data showing Cosentyx (secukinumab) demonstrated reduced flare risk versus placebo ...
Posted by Michael Wonder on 26 Dec 2021
Pfizer and BioNTech submit updated longer-term follow-up data of Comirnaty in adolescents 12 through 15 years of age to EMA
23 December 2021 - Pfizer and BioNTech today announced that they have submitted longer-term follow-up data from the companies’ pivotal Phase ...
Posted by Michael Wonder on 26 Dec 2021
Eagle Pharmaceuticals receives FDA approval for vasopressin
15 December 2021 - Company is first to file an ANDA referencing Vasostrict, which had total U.S. sales of $786 million ...
Posted by Michael Wonder on 26 Dec 2021
SIGA announces Health Canada regulatory approval of oral TPOXX
1 December 2021 - SIGA Technologies today announced that Health Canada has approved oral Tpoxx (tecovirimat) as an extraordinary use new ...
Posted by Michael Wonder on 26 Dec 2021
Takeda receives complete response letter from the U.S. FDA for TAK-721
21 December 2021 - Takeda today announced that it has received a complete response letter from the U.S. FDA in ...
Posted by Michael Wonder on 26 Dec 2021
GSK’s Jemperli (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer
15 December 2021 - GSK announces today that it has been granted Notice of Compliance with conditions for its endometrial ...
Posted by Michael Wonder on 26 Dec 2021
MHRA approves licence extension for Novartis’ targeted therapy for advanced breast cancer patients in Great Britain
23 December 2021 - Piqray (alpelisib), in combination with fulvestrant, is approved for appropriate advanced breast cancer patients with a PIK3CA ...